Literature DB >> 11387355

Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer.

S Tórtola1, R Steinert, M Hantschick, M A Peinado, I Gastinger, P Stosiek, H Lippert, W Schlegel, M A Reymond.   

Abstract

PURPOSE: To study bone marrow micrometastases from colorectal cancer patients for the presence of K-ras mutations and to compare their genotype with that of the corresponding primary tumor. PATIENTS AND METHODS: Bilateral iliac crest aspiration was performed in 51 patients undergoing surgery for colorectal cancer, and bone marrow micrometastases were detected by immunohistochemistry. The presence of K-ras mutations was determined by single-strand conformation polymorphism analysis on both primary tumors and paired bone marrow samples and was confirmed by sequencing.
RESULTS: In six patients with primary tumor mutations, it was possible to amplify a mutated K-ras gene also from the bone marrow sample. In three of those patients the pattern of K-ras mutations differed between both samples, in two patients the mutation was identical between the bone marrow and its primary tumor, and in one patient the same mutation plus a different one were found. Fifteen of 17 K-ras mutations found in primary tumors were located in codon 12, whereas in bone marrow, five of seven mutations were found in codon 13 (P =.003).
CONCLUSION: Our results demonstrate that, at least for K-ras mutations, disseminated epithelial cells are not always clonal with the primary tumor and they question the malignant genotype of bone marrow micrometastases. They also indicate that different tumoral clones may be circulating simultaneously or sequentially in the same patient. Analysis of the type of mutations suggests that cell dissemination might be an early event in colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11387355     DOI: 10.1200/JCO.2001.19.11.2837

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  17 in total

Review 1.  Biology and significance of circulating and disseminated tumour cells in colorectal cancer.

Authors:  Gunnar Steinert; Sebastian Schölch; Moritz Koch; Jürgen Weitz
Journal:  Langenbecks Arch Surg       Date:  2012-02-15       Impact factor: 3.445

2.  Epithelial cells disseminate into the bone marrow of colorectal adenoma patients.

Authors:  R Steinert; M Vieth; M Hantschick; M A Reymond
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 3.  The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

Authors:  Mustafa Khasraw; Edi Brogi; Andrew D Seidman
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

4.  Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy.

Authors:  Satu Oltedal; Ole Gunnar Aasprong; Jannicke H Møller; Hartwig Kørner; Bjørnar Gilje; Kjersti Tjensvoll; Elke M Birkemeyer; Reino Heikkilä; Rune Smaaland; Oddmund Nordgård
Journal:  Int J Colorectal Dis       Date:  2011-05-15       Impact factor: 2.571

Review 5.  Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.

Authors:  Jara M Baas; Lisanne L Krens; Henk-Jan Guchelaar; Hans Morreau; Hans Gelderblom
Journal:  Oncologist       Date:  2011-07-08

6.  Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report.

Authors:  Kenta Kawasaki; Yasuo Hamamoto; Takeshi Suzuki; Kenro Hirata; Yasutaka Sukawa; Akiyoshi Kasuga; Yuichiro Hayashi; Hiromasa Takaishi; Kaori Kameyama; Takanori Kanai
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

7.  Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.

Authors:  Xingxiang Pu; Zhizhong Pan; Ying Huang; Ying Tian; Hongqiang Guo; Lin Wu; Xuexing He; Xinggui Chen; Shaodan Zhang; Tongyu Lin
Journal:  Oncol Lett       Date:  2012-10-10       Impact factor: 2.967

8.  Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy.

Authors:  S Gattenlöhner; B Etschmann; V Kunzmann; A Thalheimer; M Hack; G Kleber; H Einsele; C Germer; H-K Müller-Hermelink
Journal:  J Oncol       Date:  2010-03-10       Impact factor: 4.375

9.  KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies.

Authors:  D Soulières; W Greer; Anthony M Magliocco; D Huntsman; S Young; M-S Tsao; S Kamel-Reid
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

Review 10.  Molecular biomarkers for the detection of metastatic colorectal cancer cells.

Authors:  Hidenori Kamiyama; Hiroshi Noda; Fumio Konishi; Toshiki Rikiyama
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.